Welcome to our dedicated page for Ani Pharmaceutic news (Ticker: ANIP), a resource for investors and traders seeking the latest updates and insights on Ani Pharmaceutic stock.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company with an active flow of corporate, clinical, and financial news. The company develops, manufactures, and commercializes therapeutics through its Rare Disease, Generics, and Brands businesses, and its communications frequently highlight progress in these areas. Investors following ANIP news can track how the Rare Disease segment, including products such as ILUVIEN and Purified Cortrophin Gel, contributes to the company’s growth alongside its generics and branded drug portfolios.
News updates for ANI often cover financial results and guidance, including quarterly earnings releases, adjusted non-GAAP metrics, and full-year outlooks. Press releases and related Form 8-K filings provide detail on net revenues by segment, the performance of key products, and management’s commentary on business trends. These disclosures also outline how Rare Disease revenues, particularly from Cortrophin Gel and ILUVIEN, compare with contributions from Generics and Brands.
ANIP news also includes clinical and medical developments, such as results from the NEW DAY clinical trial of ILUVIEN in diabetic macular edema and their presentation at major ophthalmology and retina meetings. The company reports on initiatives like the FutureVision Advisory Council, a group of retina and uveitis specialists formed to help guide its ophthalmology and retina franchise. Updates on Phase 4 trials, label transitions, and adoption trends for ILUVIEN and related products are also featured.
In addition, ANI regularly announces corporate and governance updates, including board transitions and leadership roles, as well as participation in healthcare and investor conferences hosted by organizations such as J.P. Morgan, Piper Sandler, Jefferies, H.C. Wainwright, and Morgan Stanley. These events often involve presentations or fireside chats where management discusses strategy, the transformation toward a rare disease–focused profile, and capital allocation priorities.
By monitoring ANIP news, readers can follow developments across rare disease therapeutics, generics, branded products, clinical research, and capital markets activity, all of which shape the company’s trajectory.
ANI Pharmaceuticals (ANIP) has priced an upsized offering of $275 million in 2.25% convertible senior notes due 2029. The notes will be convertible into cash and potentially shares of ANI's common stock at an initial conversion rate of 13.4929 shares per $1,000 principal amount, representing a conversion price of approximately $74.11 per share. This represents a 30% premium over the last reported sale price of $57.01 per share.
The company expects net proceeds of about $266.8 million, which will be used to fund capped call transactions and repay existing debt. ANI also plans to enter a new $325 million delayed draw term loan facility and a $75 million revolving facility. The offering is expected to settle on August 13, 2024, subject to customary closing conditions.
ANI Pharmaceuticals (Nasdaq: ANIP) has announced its intention to offer $250 million in convertible senior notes due 2029, with an option for an additional $37.5 million. The notes will be offered privately to qualified institutional buyers under Rule 144A. Key features include:
- Semi-annual interest payments
- Maturity on September 1, 2029
- Convertible under certain conditions
- Redeemable by ANI after September 1, 2027
- Repurchasable by noteholders in case of a 'fundamental change'
ANI plans to use the proceeds to repay its existing senior secured term loan and enter into capped call transactions. The company also intends to establish a new $325 million delayed draw term loan facility and a $75 million revolving facility.
ANI Pharmaceuticals reported Q2 2024 net revenues of $138 million, a YoY growth of 18.4%. Rare Disease revenues hit a record $49.2 million, up 102.4% YoY. Adjusted non-GAAP EBITDA was $33.2 million, and adjusted non-GAAP EPS was $1.02. However, they posted a net loss of $(2.7) million and a GAAP loss per share of $(0.14). The company plans to close the acquisition of Alimera Sciences in Q3 2024.
ANI raised its 2024 guidance, projecting net revenues between $540 million and $560 million, adjusted non-GAAP EBITDA of $140 million to $150 million, and adjusted non-GAAP EPS of $4.38 to $4.82. This guidance includes revenue from Cortrophin Gel, expected to be $185 million to $195 million, a YoY growth of 65% to 74%.
ANI Pharmaceuticals (NASDAQ: ANIP) has announced its plans to release second quarter 2024 financial results on Tuesday, August 6, 2024, before the market opens. The company will host a conference call at 8:30 a.m. ET on the same day to discuss the results. Nikhil Lalwani, President and CEO, and Stephen P. Carey, SVP of Finance and CFO, will lead the call.
Investors and interested parties can access the call toll-free at 800-245-3047 using the Conference ID 4619279. A live webcast and replay will be available on the company's website under the 'Investors' section. For those unable to attend, a replay will be accessible for two weeks by dialing 800-753-5212 with the same access code.
ANI Pharmaceuticals (Nasdaq: ANIP) has announced the FDA approval and launch of L-Glutamine Oral Powder, the first AA-rated generic version of Endari®. This approval showcases the company's strong R&D capabilities and execution. The product aims to provide patients and healthcare providers with access to high-quality therapeutics.
Key points:
- L-Glutamine Oral Powder is an Abbreviated New Drug Application (ANDA)
- U.S. annual sales for the product are approximately $20.1 million (based on May 2024 IQVIA data)
- The launch demonstrates ANI's commitment to expanding its product portfolio and addressing market needs
ANI Pharmaceuticals has announced the FDA approval and launch of Naproxen Delayed-Release Tablets, USP, which is a generic version of EC-Naprosyn®. This product received first-cycle approval, allowing ANI to quickly commercialize it.
The U.S. market for Naproxen Delayed-Release Tablets is valued at approximately $36.7 million annually, based on April 2024 IQVIA data. Nikhil Lalwani, President and CEO of ANI, emphasized the company's commitment to growth through effective new product launches.
ANI Pharmaceuticals announced that its CEO, Nikhil Lalwani, has won the EY Entrepreneur Of The Year 2024 New Jersey Award. The award, given by Ernst & Young LLP, recognizes outstanding entrepreneurial vision, leadership, and impact on patients and growth. Lalwani, CEO since September 2020, has increased the company's Enterprise Value by 2.8 times. This award makes Lalwani eligible for the National and World Entrepreneur Of The Year Awards. The program highlights leaders who have significantly transformed their organizations.
ANI Pharmaceuticals announced the acquisition of Alimera Sciences to expand its Rare Disease segment, which will drive future growth.
The acquisition involves $5.50 per share in cash and contingent value rights of up to $0.50 per share, valuing Alimera at $381 million.
This deal adds $105 million in branded revenue and is expected to strengthen ANI's ophthalmology portfolio with ILUVIEN and YUTIQ.
The acquisition is projected to contribute $35-$38 million in 2025 adjusted non-GAAP EBITDA and $10 million in cost synergies.
ANI expects high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025, with further growth thereafter.
The transaction is anticipated to close in Q3 2024, subject to regulatory and shareholder approvals.
ANI Pharmaceuticals announced that CEO Nikhil Lalwani will present at the 2024 Jefferies Global Healthcare Conference in New York City. The presentation is scheduled for June 5, 2024, at 4:30 PM ET. Interested parties can attend the webcast through a provided link or schedule 1-on-1 meetings by contacting their Jefferies representative.
ANI Pharmaceuticals announced the launch of Kionex® Suspension, a Sodium Polystyrene Sulfonate Suspension USP, for oral or rectal use. This product is the only commercially available therapeutically equivalent to the reference listed drug (RLD) SPS® Suspension. The launch highlights ANI's capability to introduce complex generics with market competition. According to President and CEO Nikhil Lalwani, this achievement demonstrates the company's strong R&D team and their ability to meet FDA's updated guidelines. The U.S. annual sales for this drug category total approximately $30.3 million, based on March 2024 IQVIA data.